Image source: Pacira Pharmaceuticals.
Continue Reading Below
What:Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) are rallying 19.7% at 1:00 p.m. EDT after the company reported second-quarter financials that outpaced industry watchers' estimates.
So what: Pacira Pharmaceuticals generates 96% of its revenue from Exparel, a surgical pain medication, and in the second quarter, rising demand for Exparel resulted in sales of $69.6 million, up 17.7% year over year, and earnings per share (EPS) of $0.19, which was $0.16 ahead of analyst expectations.
"The second quarter marked another period of double-digit, year-over-year revenue growth as we advanced multiple initiatives to support Exparel in the latter half of this year and into 2017," said Pacira CEO and Chairman Dave Stack. "Our aggressive investments in patient outreach and clinical development, as well as commercial and educational programs, are progressing as planned. For the rest of this year, we look forward to continuing the strong progress we've made with the Phase 4 randomized controlled trials in strategic orthopedic surgeries, Phase 3 nerve block studies, enhanced recovery protocols in soft tissue procedures and data presentations on bundled payments. We also anticipate increasing our public relations and advocacy efforts to bring attention to addressing the opioid epidemic by providing an alternative to opioids in the acute postsurgical setting, where epidemicoften starts."
The strong results suggest that doctors are increasingly turning to Exparel, rather than opioids, to relieve patient pain following procedures, and given that the market for opioid pain relief is worth billions of dollars annually, the company's runway for growth could be long.
Worldwide, pain drugs are the second-biggest class of drugs -- about 300 million prescriptions written last year were worth an estimated $24 billion.
Continue Reading Below
Now what: Pacira is positioning Exparel as a better-than-opioid option and studies that confirm its ability to provide pain relief in multiple settings could lead to label expansions that significantly expand the drug's addressable market. For example,the company plans to launch Exparel for use in oral surgery, such as wisdom teeth procedures, in the coming months.
Overall, Pacira's double-digit growth and profitability make it an intriguing stock for biotech investors to own, especially given that doctors are increasingly looking for non-opioid pain solutions in the wake of rising opioid abuse. Pacira's management is guiding for sales of at least $270 million, up from $249 million in 2015, and the various revenue tailwinds could lead to even greater sales next year.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him onTwitter where he goes by the handle@ebcapital to see more articles like this.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.